Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail targets Virus-Linked cancers in early trial

NCT ID NCT04902443

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kaposi sarcoma, lymphomas, or other virus-associated cancers that haven't responded to standard treatment can join, including those with HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

pomalidomide and nivolumab

What this could lead to

If it works, this could point toward a new treatment option for several hard-to-treat virus-related cancers.

What could go wrong

This is an early phase 1 trial with only 58 participants, so safety and dosing are still being figured out. It may not work for all cancer types, and side effects from the drug combination are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma AIDS cervical carcinoma Epstein-Barr virus-associated gastric carcinoma Epstein-Barr virus-associated mesenchymal tumor Hodgkins lymphoma Kaposi's sarcoma nasopharyngeal carcinoma oropharyngeal carcinoma primary effusion lymphoma virus associated tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV/KSHV-ASSOCIATED LYMPHOMAS KAPOSI SARCOMA VIRAL ASSOCIATED MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••